Dupixent vs Sotyktu
A side-by-side look at two autoimmune medications advertised on TV. Informational only — not medical advice.
Maintained by TVPills Editorial Team · Site updated November 4, 2026 (not a product-label review)
| Attribute | US Dupixent | US Sotyktu |
|---|---|---|
| Generic name | dupilumab Unverified catalogue summary (Generic name) for Dupixent in US; not checked against current local product information. | deucravacitinib Unverified catalogue summary (Generic name) for Sotyktu in US; not checked against current local product information. |
| Drug class | See official local label Unverified catalogue summary (Drug class) for Dupixent in US; not checked against current local product information. | See official local label Unverified catalogue summary (Drug class) for Sotyktu in US; not checked against current local product information. |
| Treats | See official local label Unverified catalogue summary (Treats) for Dupixent in US; not checked against current local product information. | Adult moderate-to-severe plaque psoriasis; adult active psoriatic arthritis Unverified catalogue summary (Treats) for Sotyktu in US; not checked against current local product information. |
| Category | Autoimmune Unverified catalogue summary (Category) for Dupixent in US; not checked against current local product information. | Autoimmune Unverified catalogue summary (Category) for Sotyktu in US; not checked against current local product information. |
| Manufacturer | Regeneron Pharmaceuticals, Inc. Unverified catalogue summary (Manufacturer) for Dupixent in US; not checked against current local product information. | Bristol-Myers Squibb Company (US distributor) Unverified catalogue summary (Manufacturer) for Sotyktu in US; not checked against current local product information. |
| Year approved | — Unverified catalogue summary (Year approved) for Dupixent in US; not checked against current local product information. | — Unverified catalogue summary (Year approved) for Sotyktu in US; not checked against current local product information. |
| Catalogue warning level | Safety summary withheld — check official label Unverified catalogue summary (Catalogue warning level) for Dupixent in US; not checked against current local product information. | Safety summary withheld — check official label Unverified catalogue summary (Catalogue warning level) for Sotyktu in US; not checked against current local product information. |
| Est. TV ad spend | $390M | $130M |
| Side effects and serious risks | — Unverified catalogue summary (Side effects and serious risks) for Dupixent in US; not checked against current local product information. | — Unverified catalogue summary (Side effects and serious risks) for Sotyktu in US; not checked against current local product information. |
Sources and editorial standards
Use the current DailyMed labels to verify approved uses, boxed warnings, and side effects for each medication. Label results can differ by product, strength, and formulation.
Page updated November 4, 2026; the linked resources have not necessarily been reviewed on this date.
Frequently asked questions
Is Dupixent or Sotyktu better?
This directory does not compare clinical effectiveness or safety. Listing Dupixent and Sotyktu together does not establish shared approved indications, equivalence or suitability as substitutes. Consult the correct local labels and your prescriber.
What's the difference between Dupixent and Sotyktu?
The table shows catalogue identification and estimated advertising information for Dupixent and Sotyktu, not a verified medical comparison. Medical descriptions, mechanisms and safety summaries are withheld.
Which one spends more on TV ads?
Dupixent has the larger estimated TV advertising budget of the two.